Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks. - Rothenberg ML; Kuhn JG; Schaaf LJ; Rodriguez GI; Eckhardt SG; Villalona-Calero MA; Rinaldi DA; Hammond LA; Hodges S; Sharma A; Elfring GL; Petit RG; et al. (Annals of oncology : official journal of the European Society for Medical Oncology, 2001)